



Clinical multimodality imaging: Pichler and colleagues offer a focus on PET/MRI instrumentation as the next generation of clinical molecular imaging, including technical evolution and the range of potential applications. **Page 333**




Monte Carlo method: Bolch provides a brief history and perspective on nuclear medicine uses of the Monte Carlo method, a class of computational algorithms that rely on repeated random samplings to compute physical quantities. **Page 337**

^{18}F -FLT PET with CTLA4 blockade: Ribas and colleagues evaluate the role of whole-body molecular imaging in patients with metastatic melanoma receiving tremelimumab, a cytotoxic T-lymphocyte-associated antigen 4-blocking antibody. . . . **Page 340**




^{18}F -FDG uptake in normal breast: Mavi and colleagues investigate whether and how age, menopausal state, and tissue density are related to ^{18}F -FDG uptake in normal glandular breast tissue. **Page 347**




Predictive PET in NETs: Campana and colleagues explore the use of standardized uptake values from ^{68}Ga -DOTANOC PET imaging as accurate noninvasive markers for disease prognosis in patients with neuroendocrine tumors. **Page 353**

PET and surgical staging in cervical cancer: Kang and colleagues report on a metaanalysis of the diagnostic performance of ^{18}F -FDG PET in detecting para-aortic lymph node metastasis in patients with cervical cancer. **Page 360**

Arterial wall toxicity in NHL RIT: Hobbs and colleagues look at absorbed doses to the arterial wall in patients undergoing radioimmunotherapy for non-Hodgkin lymphoma to assess the potential for delayed toxicity. **Page 368**



Para-aortic sentinel node localization: Vermeeren and colleagues describe and evaluate preoperative SPECT/CT for lymphatic mapping and a portable γ -camera for intraoperative radioguidance in patients with para-aortic sentinel nodes. **Page 376**




Salvage therapy with ^{177}Lu -octreotate: van Essen and colleagues detail the effects of additional therapy with this radiolabeled somatostatin analog in patients with progressive gastroenteropancreatic or bronchial neu-

roendocrine tumors who had benefited from previous therapeutic cycles. **Page 383**


$^{99\text{m}}\text{Tc}(\text{CO})_3(\text{NTA})$ renal tracer: Taylor and colleagues compare the pharmacokinetics of this tricarbonyl core agent with those of ^{131}I -ortho-iodohippuran, the clinical gold standard for measurement of effective renal plasma flow, in healthy volunteers. **Page 391**

^{90}Y -DOTATOC treatment of glioblastoma: Heute and colleagues report on the use of this somatostatin receptor radiopharmaceutical in the treatment of patients with high-grade malignant gliomas. . . . **Page 397**




Cost-effectiveness of PET and PET/CT: Buck and colleagues provide an educational overview and evaluation of methodologies for cost-effectiveness studies of PET and PET/CT in oncology. **Page 401**

Endocardial versus epicardial cell injection: Mitchell and colleagues compare the cell retention and clearance kinetics of subepicardial and subendocardial techniques for stem cell delivery to recently infarcted myocardium. **Page 413**




Enhanced melanoma uptake: Guo and colleagues examine the effect of the ring size of the radiolabeled lactam bridge-cyclized α -melanocyte-stimulating hormone peptide on its melanoma-targeting properties and discuss the implications for imaging and treatment. **Page 418**



Targeting prostate cancer cells: He and colleagues evaluate the tumor-targeting capabilities of a radiolabeled internalizing human antibody fragment to provide high contrast in a mouse model of human prostate carcinoma. **Page 427**


Knottin peptide-based ultrasound agent: Willmann and colleagues describe a new class of targeting ligands for contrast-enhanced ultrasound imaging of tumor angiogenesis using microbubbles conjugated to integrin-binding knottin peptides. **Page 433**

Benzamide PET of melanoma: Denoyer and colleagues evaluate the novel melanin probe ^{118}F -MEL050 for PET imaging of primary and metastatic melanoma using murine models. **Page 441**



^{68}Ge calibration methodology: Zimmerman and Cessna describe a technique for calibrating ^{68}Ge radioactivity content in a commercially available source for activity calibrators in a way that is traceable to the national standard and extend this approach to ^{18}F calibration. . . . **Page 448**


Labeling octreotide with ^{18}F : Laverman and colleagues present a 2-step, 1-pot method for rapid and efficient labeling of peptides with ^{18}F **Page 454**




Monte Carlo cellular dosimetry: Cai and colleagues compare Monte Carlo N-particle ^{111}In self- and cross-doses to breast cancer cell nuclei with doses calculated by other methods and determine whether Monte Carlo results can predict cell survival. **Page 462**

Animal models for dose assessment: Keenan and colleagues describe a series of anatomically realistic mouse and rat whole-body phantoms and use these mod-

els to facilitate dose calculations in various rodent species. **Page 471**



^{111}In -NLS-trastuzumab radiosensitization: Costantini and colleagues elucidate the mechanisms by which methotrexate radiosensitizes *HER2*-positive human breast cancer cells to the ^{111}In -trastuzumab modified with nuclear-localization sequence peptides and determine the potential sensitizing effects of paclitaxel and doxorubicin when combined with this radiopharmaceutical. **Page 477**



Improving anti-CD66 mAb RIT: Kletting and colleagues review the development of a physiologically based pharmacokinetic model capable of describing biodistribution and extrapolating between different doses of anti-CD66 monoclonal antibody in radioimmunotherapy. **Page 484**

ON THE COVER

Monte Carlo N-particle simulation has been shown to compare well with 2 analytic methods in the calculation of subcellular S values. The radii of cells and nuclei have a profound effect on S values and may vary considerably. The cell and nucleus diameters of 6 commonly used breast cancer cell lines have been measured and reported for the first time.

See page 467.

